Glucagon as a target for the treatment of Type 2 diabetes

By Sloop Kyle W   Michael M Dodson   Moyers Julie S  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 3, 2005-06 ,pp. : 593-600

Informa Healthcare

Access to resources Recommend Favorite

Glucagon antagonists for the treatment of Type 2 diabetes

By Connell R.D.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 6, 1999-06 ,pp. : 701-709

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

By Yu F   Takahashi T   Moriya J   Kawaura K   Yamakawa J   Kusaka K   Itoh T   Sumino H   Morimoto S   Kanda T  

The Journal of International Medical Research, Vol. 34, Iss. 3, 2006-05 ,pp. : 297-302

Field House Publishing

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

Effects of Olmesartan Medoxomil, an Angiotensin II Type 1 Receptor Antagonist, on Plasma Concentration of B-Type Natriuretic Peptide, in Hypertensive Patients with Type 2 Diabetes Mellitus: A Preliminary, Observational, Open-Label Study

By Kawai Toshihide   Takei Izumi   Shimada Akira  

Clinical Drug Investigation, Vol. 31, Iss. 4, 2011-04 ,pp. : 237-245

Adis International

Access to resources Recommend Favorite